Treating ROS1-positive advanced non-small cell lung cancer (NSCLC) can be challenging, and most patients develop disease progression and resistance on first-line therapeutic agents. In this on-demand video, join us for an expert-led discussion on new and emerging evidence, guideline-recommended testing and treatment strategies, and updates in ROS1-positive advanced NSCLC. Don’t miss the 3D medical animation developed in partnership with BioDigital focused on mechanisms of action of new and emerging therapeutic agents for ROS1-positive NSCLC.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/transforming-nsclc-care-latest-insights-ros1-targeted-therapies
- Start Date: 2024-09-27 05:00:00
- End Date: 2024-09-27 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 89750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest